Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948032 · ClinicalTrials.gov registry record · Phase 1
Study of BLU-808 in Healthy Adult Participants
A Phase 1 study of Healthy Participants, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT06948032 is a Phase 1 study of Healthy Participants that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 95 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (46% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06948032, a Phase 1 study of Healthy Participants, has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effect of multiple doses of BLU-808 on the single-dose pharmacokinetics (PK) of midazolam. Part 3 is an open-label, 2-sequence, 2-period, food effect (FE) study in healthy adult participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG BLU-808
Study Locations (1)
Nebraska
- Celerion, Inc. - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2025-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948032
The ClinicalTrials.gov registry entry for NCT06948032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (46% higher). The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06948032 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT06948032 about?
NCT06948032 is a clinical study titled "Study of BLU-808 in Healthy Adult Participants". This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effec...
What is the current status of trial NCT06948032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2024-08-07. Estimated completion is 2025-01-21.
What conditions does trial NCT06948032 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06948032?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), BLU-808 (DRUG).
Who is sponsoring clinical trial NCT06948032?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948032 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.